

FLORIDA CANCER DATA SYSTEM

FCDS DAM 2026

Summary of Changes

A comprehensive review of the FCDS Data Acquisition Manual — for registrars, abstractors, and reporting facilities.

2026 Reporting Year



Megsys Herna, BA, ODS-C
FCDS Virtual Annual Conference
September 9-10, 2026

Purpose of the 2026 Updates

1

Improve clarity

Better clarity and organization make the manual easier to navigate and apply.

2

Align to standards

Reporting instructions aligned with current standard-setting requirements.

3

Expand resources

Updated examples, tables, links, and coding guidance throughout.

4

Support consistency

Consistent cancer data collection and reporting across facilities.

AT A GLANCE

Key Themes Across the Manual

Changes are not limited to one section — they appear across eligibility, casefinding, demographics, tumor information, treatment, and appendices.

01

Reorganized

Content restructured for better usability and easier navigation.

02

Updated

Refreshed links, references, and standard-setting resources.

03

Expanded

More tables and examples to improve interpretation.

04

Clarified

Sharper coding rules, definitions, and reporting expectations.

SECTION I

Case Eligibility Updates

KEY UPDATE

Jan 1, 2026

Revised FCDS reportability rule now applies to cases diagnosed on or after this date, aligning with CoC.

- Revised list of reportable in situ and invasive neoplasms, with added histology codes.
- Added ICD-O-3.2 updates and a new alphabetic reference table for 2026.
- Added guidance on LAMN (Low-Grade Appendiceal Mucinous Neoplasm).
- New tables for ambiguous terms that do — and do not — constitute a diagnosis.
- Clarified non-reportable skin cancers, including Bowen's disease (C44.0–C44.9).

SECTION I

Casefinding Updates

KEY UPDATE

5 areas

Expanded guidance helps facilities catch every reportable case within their own workflows.

- Added explanatory language on the purpose and importance of casefinding.
- Revised and reformatted the sources to review for missed reportable cases.
- Outlined more specific examples to be adapted to each facility.
- Updated the ICD-10-CM 2026 casefinding list with new reportable tumor codes.
- Added disposition codes and a table for tracking non-reportable cases.

SECTION I

Abstracting & Reference Materials

KEY UPDATE

Refreshed

Current desktop references and clearer support channels for coding questions.

- Updated links in the Required and Recommended Desktop References table.
- Refreshed references in Appendix P (2026 References & Resources for Registrars).
- Added a “Where to Go for Submitting Technical Questions” table.
- New FCDS disposition code table; obsolete codes 998 and 999 removed.
- Added optional minimal instructions for abstracting historical cases.

SECTION II

Patient Demographics Updates

KEY UPDATE

Item 225

New NAACCR data item for Sex Assigned at Birth, added to the demographics grid.

- Purpose statements added to each NAACCR data item.
- New NAACCR data item 225 detailed for sex assigned at birth.
- Added related link (Appendix E) to item 190, Spanish/Hispanic origin.
- Updated USPS ZIP lookup link for item 100, address at diagnosis.
- Updated USPS ZIP lookup link for item 1830, current address.

SECTION II

Tumor Information Updates

KEY UPDATE

13 items

The most extensively revised area — content updates plus new coding tools.

- Purpose added to all data items; links updated and rules checked against standard setters.
- Updated Date of Diagnosis example; new table to estimate date by primary site.
- ~~Laterality must be 9 for C80.9.~~
- In situ synonyms updated.
- New tables for coding LVI (from STORE) and for tumor size code 999.
- Grade Manual updated to v3.3; behavior code 2 descriptions revised.

SECTION II

Treatment Information Updates

KEY UPDATE

STORE + SEER

Treatment guidance aligned to current STORE and SEER coding resources.

- Updated treatment links and references, including SEER Appendix C and the 2026 STORE manual.
- Added histotripsy under other forms of thermal ablation.
- Updated surgery coding structure and guidance for primary site A980.
- Added SLN code 2 for all solid tumor neoplasms where the procedure is performed.
- Updated chemotherapeutic agents; added information on inhibitors and taxanes.

REFERENCE

Appendices & Resources

Key reference materials have been added or reorganized — review the appendices carefully.



Appendix Q

New appendix added for the 2026 manual.



Appendix R

New appendix introduced for the 2026 manual.



Appendix S

ICD-O-3.2 Updates for 2026 — formerly Appendix R.

IN SUMMARY

Key Takeaways

1

Updates are everywhere

The DAM 2026 includes revisions throughout the entire manual.

2

Review the full document

Registrars and abstractors should read the complete manual carefully.

3

Stronger, clearer guidance

Changes improve consistency, clarity, and alignment with current standards.

4

Know where to ask

Direct questions to FCDS through the appropriate technical support channels.

QUESTIONS & DISCUSSION

Share feedback on areas that need clarification, and reach out to FCDS for follow-up support.

Contact FCDS directly for any inquiries about the DAM 2026.